Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals (Nasdaq: ACAD) will report first quarter 2026 financial results on May 6, 2026, after U.S. market close. The company will host a conference call and webcast on May 6, 2026 at 4:30 p.m. ET, accessible via acadia.com and archived through August 15, 2026.
Registration is required to receive dial-in details and a unique PIN. Acadia highlights a commercial portfolio with FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome and ongoing mid-to-late stage programs in Alzheimer’s and Lewy body dementia psychosis.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that DAYBUE STIX (trofinetide) powder for oral solution is now broadly available in the United States for treatment of Rett syndrome in patients two years and older. The FDA approved the formulation in December 2025 and bioequivalence testing showed comparable exposure to the original DAYBUE oral solution. DAYBUE STIX is dye- and preservative-free, comes in single-use packets, can be mixed with water-based drinks for taste customization, and is supported by Acadia Connect for financial and prescription assistance. The original oral solution remains available.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 8:00 a.m. ET. A live webcast will be accessible on the company website under Investors, with an archived recording available for about one month.
Acadia highlighted its commercial portfolio including FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and its mid- to late-stage pipeline in Alzheimer’s disease psychosis and Lewy body dementia psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) appointed Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Audit Committee and brings senior biopharma finance experience, including his role as SVP, Finance at Vertex since March 2020.
This board addition is positioned to strengthen financial and operational oversight as Acadia advances its commercial portfolio and pipeline across neurological and rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) said on March 2, 2026 that the EMA CHMP issued a negative opinion on trofinetide for Rett syndrome; the company intends to request a re-examination.
Acadia noted the pivotal LAVENDER trial met its co-primary and key secondary endpoints, while CHMP raised concerns about effect magnitude at 12 weeks, symptom coverage, and longer-term discontinuations. Trofinetide is approved in the US, Canada and Israel.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q4 2025 GAAP total revenues of $284M and FY2025 GAAP total revenues of $1.07B, representing 9% and 12% YoY growth. Non‑GAAP adjusted FY2025 revenues were $1.08B. Q4 NUPLAZID GAAP net sales were $174M and DAYBUE GAAP net sales were $110M.
The company recorded a $20M IRA rebate change in estimate affecting NUPLAZID GAAP sales; FY2026 guidance calls for $1.22–$1.28B total revenues and NUPLAZID sales of $760–$790M.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in three investor events in March 2026, including TD Cowen's 46th Annual Health Care Conference and The Citizens Life Sciences Conference.
Fireside chats are scheduled for March 2, 2026 at 11:10 a.m. ET in Boston and March 11, 2026 at 1:05 p.m. ET in Miami Beach. Live webcasts and archived recordings will be available on the company website for about one month after each presentation.
Acadia Pharmaceuticals (Nasdaq: ACAD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after U.S. market close. Management will host a conference call and webcast on February 25, 2026 at 4:30 p.m. ET, available via the company's investor website and archived through May 24, 2026.
Registration is required for dial-in details and a unique PIN; the webcast link will be posted on acadia.com under Investors.
Acadia Pharmaceuticals (NASDAQ: ACAD) said the CHMP at the European Medicines Agency issued a negative trend vote on its Marketing Authorization Application for trofinetide for Rett syndrome following an oral explanation.
Acadia expects a negative opinion, intends to request a CHMP re-examination once the opinion is formally adopted, and noted trofinetide is approved in the US, Canada, and Israel with >1,000 patients on active treatment globally.
Acadia Pharmaceuticals (Nasdaq: ACAD) provided business and pipeline updates at the 44th J.P. Morgan Healthcare Conference on January 13, 2026. Management reiterated a 2028 projected combined net sales of ~$1.7 billion (NUPLAZID ~ $1.0B; DAYBUE ~ $0.7B). Key near‑term catalysts include top‑line Phase 2 RADIANT results for remlifanserin expected Aug–Oct 2026 and multiple regulatory milestones for trofinetide (DAYBUE), including FDA approval of DAYBUE STIX (Dec 12, 2025) with limited U.S. availability in Q1 2026 and broader launch in Q2 2026.
Other items: Israel approval for DAYBUE oral solution, EMA CHMP opinion anticipated Q1 2026, Japan Phase 3 trofinetide readout expected Oct 2026–Mar 2027, and plans to initiate five Phase 2/3 studies with four readouts by end of 2027.